ArticleJournal of the National Cancer Institute2026
Cancer-associated arterial thromboembolism: real-world burden from a nationwide electronic health record database.
Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundArterial thromboembolism (ATE), including myocardial infarction (MI) and ischemic stroke (iCVD), is increasingly recognized in patients with cancer; however, contemporary population-level data remain limited.
methodsWe conducted a retrospective cohort study using Epic Cosmos to identify adults with incident cancer (2018 to 2023). ATE events (MI and iCVD) were ascertained using validated inpatient ICD-10-CM billing codes. Cumulative incidence was estimated using competing risk method with death as a competing event. Multivariable Cox proportional hazards models with LASSO penalization were used for variable selection and risk estimation. Systemic therapy (for ATE) and ATE onset (for mortality) were modeled as time-varying covariates.
resultsAmong 1,740,618 patients, the cumulative incidence of ATE was 2.4%, 3.4%, and 4.9% at 1, 2, and 5 years, respectively. Incidence was highest in acute leukemia (5.5%), lung (5.1%), and pancreatic (4.9%), and lowest in prostate (1.5%), uterine (1.5%), breast (0.9%), and testicular cancers (0.5%). Independent factors associated with ATE onset included cancer-specific characteristics (cancer type, metastatic disease, and systemic therapy); pre-existing cardiovascular disease (prior MI, iCVD, heart failure, peripheral vascular disease); cardiovascular risk factors (older age, male sex, diabetes, hypertension, renal disease); and other clinical and laboratory variables. In an analysis adjusted for baseline confounders, time-varying onset of ATE was associated with an approximately 3-fold increase in mortality.
conclusionsATE incidence and risk vary significantly across cancer populations. The development of ATE is associated with adverse prognosis. These findings highlight the importance of adapted cardio-oncology risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.